#AIDS Institute

This ruling will affect millions and erect barriers to care, say patient advocacy groups representing those with cancer, HIV and more.

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.

HIV, hepatitis and LGBTQ advocates lead the charge. Plus, a study suggests that long-acting injectable PrEP isn’t cost effective.

People 55 and older make up 37% of the U.S. HIV population. Most are undetectable. What’s more, PrEP use increased among this age group.

The Supreme Court upholds the Affordable Care Act for a third time. Here’s a look at responses from health care advocates.

The Viral Hepatitis National Strategic Plan for the United States, released by HHS, offers a road map for the next five years.

Hepatitis A and B can be prevented with vaccines, and hepatitis C can be cured with antiviral treatment.

A coalition of LGBT groups sues the Trump administration over the rule. The lawsuit is “Whitman-Walker Clinic v. HHS.”

But it comes with deep cuts to Medicare, Medicaid, Social Security, cancer funds and other health and science programs.

As sexually transmitted infections spike to all-time highs, these 17 advocacy groups join forces to reverse the trend.

Efforts to control viral hepatitis are falling behind, in part because of the growing opioid epidemic and homelessness crisis.

Older people who learn they have HIV are likely to have been positive for 4.5 years—the longest diagnosis delay of any age group.

The change targets LGBT people and those with chronic conditions. Here’s how patient groups and Lambda Legal respond.

The Trump administration had proposed changing which meds were covered, including HIV and cancer drugs.

Insurance companies can no longer implement harmful co-pay accumulator policies.

A roundup of statements